Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
AssigneeClaragen, Inc. and U.S. Government
InventorsAprile L. Pilon, Anil B. Mukherjee, Zhongjian Zhang
Life of this patent
Estimating the term…
Abstract
Method for treatment of inflammatory and fibrotic conditions in vivo using pure rhUG is disclosed. Method for treating or preventing inflammatory or fibrotic conditions characterized by a deficiency of endogenous functional UG is also disclosed. Compositions containing pure rhUG, optionally also containing lung surfactant, and assay procedures for detection of UG-fibronectin complexes, are also provided.
Claims10
A method for inhibiting fibronectin-fibronectin binding and/or fibronectin deposition comprising exposing the fibronectin to recombinant human uteroglobin (rhUG) wherein the rhUG binds the fibronectin and inhibits fibronectin-fibronectin binding and/or fibronectin deposition.
Dependencies are inferred from the claim text.